ANGO
Angiodynamics Inc Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$11.99Close
$500.0MMarket cap
$9.70 – $16.1352-week range
Early-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 36 · weaker than 64% of stocks over 12 months
- Far from its high 26% below its 52-week high
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
26%
1wk
down 3.1%
price change
1mo
down 22.0%
price change
12-month return
down 1%
market up 11% ·
its own down 12%
F-score
5 / 9
Mixed
Altman Z
1.78
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.9×
price / book
Earnings yield
down 8.9%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
up 9%
year on year
EPS growth
—
latest quarter
Sales growth
up 7%
latest quarter · -1 pts
ROE
down 21%
return on equity
Free cash margin
0%
$508,000 FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-15M → $1M)
- Revenue reaccelerating (-4% then +9%)
Trade setup
ATR%
4.9%
$0.58 a day · 2×ATR $10.82
RS
36 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.07
50 sessions
Implied move
—
no scheduled report
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Oct 8, 2026
Last shock
Oct 8, 2026-21% in one session5.7× volumeon results+7% since
Financials
- Gross 55%
- Net -11%
- Free cash 0%
- Cash
- Long-term debt
| FY2021May 31, 2021 | FY2022May 31, 2022 | FY2023May 31, 2023 | FY2024May 31, 2024 | FY2025May 31, 2025 | FY2026May 31, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $291.0M | $316.2M | $338.8M | $303.9M | $292.5M | $320.2M |
| Gross margin | 54% | 52% | 51% | 51% | 54% | 55% |
| Operating income | -$35.3M | -$28.5M | -$51.2M | -$192.4M | -$40.0M | -$39.9M |
| Net income | -$31.5M | -$26.5M | -$52.4M | -$184.3M | -$34.0M | -$36.7M |
| Net margin | -11% | -8% | -15% | -61% | -12% | -11% |
| Earnings per share | -$0.82 | -$0.68 | -$1.33 | -$4.59 | -$0.83 | -$0.88 |
| Free cash flow | $18.9M | -$11.5M | -$3.7M | -$30.7M | -$14.6M | $508,000 |
| Free cash margin | 6% | -4% | -1% | -10% | -5% | 0% |
| Cash | $48.2M | $28.8M | $44.6M | $76.1M | $55.9M | $53.9M |
| Long-term debt | $20.0M | $25.0M | $49.8M | $0 | — | — |
| Shareholders' equity | $439.5M | $424.5M | $378.3M | $205.6M | $183.0M | $170.8M |
| Shares outstanding | 38.55m | 39.17m | 39.61m | 40.43m | 40.99m | 41.70m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 8, 2026 | Quarterly ↗ | Aug 31, 2026 | 38d |
| Jul 14, 2026 | Annual ↗ | May 31, 2026 | 44d |
| Apr 2, 2026 | Quarterly ↗ | Feb 28, 2026 | 33d |
| Jan 6, 2026 | Quarterly ↗ | Nov 30, 2025 | 37d |
| Oct 2, 2025 | Quarterly ↗ | Aug 31, 2025 | 32d |
| Jul 18, 2025 | Annual ↗ | May 31, 2025 | 48d |
| Apr 2, 2025 | Quarterly ↗ | Feb 28, 2025 | 33d |
| Jan 8, 2025 | Quarterly ↗ | Nov 30, 2024 | 39d |
| Oct 3, 2024 | Quarterly ↗ | Aug 31, 2024 | 33d |
| Jul 25, 2024 | Annual ↗ | May 31, 2024 | 55d |
| Apr 9, 2024 | Quarterly ↗ | Feb 29, 2024 | 40d |
| Jan 8, 2024 | Quarterly ↗ | Nov 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 8, 2026 | Results · Regulation FD ↗ |
| Oct 8, 2026 | Material agreement · Director or officer change ↗ |
| Jul 14, 2026 | Results · Regulation FD ↗ |
| Apr 23, 2026 | Other events ↗ |
| Apr 2, 2026 | Results · Regulation FD ↗ |
| Feb 3, 2026 | Director or officer change ↗ |
| Jan 14, 2026 | Regulation FD ↗ |
| Jan 6, 2026 | Results · Regulation FD ↗ |
| Nov 12, 2025 | Shareholder vote ↗ |
| Oct 2, 2025 | Results · Regulation FD ↗ |
| Jul 15, 2025 | Results · Regulation FD ↗ |
| May 28, 2025 | Material agreement · New obligation ↗ |